HRP20110695T1 - Kombinacije beta-2-adrenoceptorskog agonističkog benzotiazolona - Google Patents
Kombinacije beta-2-adrenoceptorskog agonističkog benzotiazolona Download PDFInfo
- Publication number
- HRP20110695T1 HRP20110695T1 HR20110695T HRP20110695T HRP20110695T1 HR P20110695 T1 HRP20110695 T1 HR P20110695T1 HR 20110695 T HR20110695 T HR 20110695T HR P20110695 T HRP20110695 T HR P20110695T HR P20110695 T1 HRP20110695 T1 HR P20110695T1
- Authority
- HR
- Croatia
- Prior art keywords
- ethyl
- active ingredient
- preparation
- bromide
- pharmaceutical product
- Prior art date
Links
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 title 1
- 230000001270 agonistic effect Effects 0.000 title 1
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 title 1
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 title 1
- 239000004480 active ingredient Substances 0.000 claims abstract 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract 7
- 229940127557 pharmaceutical product Drugs 0.000 claims abstract 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 2
- 238000002360 preparation method Methods 0.000 claims 7
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 claims 4
- 229960000257 tiotropium bromide Drugs 0.000 claims 4
- VSWPGAIWKHPTKX-UHFFFAOYSA-N 1-methyl-10-[2-(4-methyl-1-piperazinyl)-1-oxoethyl]-5H-thieno[3,4-b][1,5]benzodiazepin-4-one Chemical compound C1CN(C)CCN1CC(=O)N1C2=CC=CC=C2NC(=O)C2=CSC(C)=C21 VSWPGAIWKHPTKX-UHFFFAOYSA-N 0.000 claims 3
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims 3
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 3
- ASMXXROZKSBQIH-VITNCHFBSA-N aclidinium Chemical compound C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1 ASMXXROZKSBQIH-VITNCHFBSA-N 0.000 claims 3
- 229960005012 aclidinium bromide Drugs 0.000 claims 3
- 229940015042 glycopyrrolate Drugs 0.000 claims 3
- 239000003149 muscarinic antagonist Substances 0.000 claims 3
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 claims 3
- 229960000797 oxitropium Drugs 0.000 claims 3
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 claims 3
- 229960004633 pirenzepine Drugs 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- 229950004351 telenzepine Drugs 0.000 claims 3
- WORMGNDAXQYVAV-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-n-[2-[2-(4-hydroxy-2-oxo-3h-1,3-benzothiazol-7-yl)ethylamino]ethyl]-3-(2-naphthalen-1-ylethoxy)propanamide;dihydrobromide Chemical compound Br.Br.C1=CC=C2C(CCOCCC(=O)N(CCNCCC=3C=4SC(=O)NC=4C(O)=CC=3)CCN(CC)CC)=CC=CC2=C1 WORMGNDAXQYVAV-UHFFFAOYSA-N 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- OFNNVZSSXHTGRK-UHFFFAOYSA-N propanamide dihydrobromide Chemical compound Br.Br.C(CC)(=O)N OFNNVZSSXHTGRK-UHFFFAOYSA-N 0.000 claims 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 abstract 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Natural products CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Farmaceutski proizvod, naznačen time, da sadrži u kombinaciji, prvi aktivni sastojak koji je N-[2-(Dietilamino)etil]-N-(2-{[2-(4-hidroksi-2-okso-2,3-dihidro-1,3-benzotiazol-7-il)etil]amino}etil)-3-[2-(1-naftil)
Claims (8)
1. Farmaceutski proizvod, naznačen time, da sadrži u kombinaciji, prvi aktivni sastojak koji je N-[2-(Dietilamino)etil]-N-(2-{[2-(4-hidroksi-2-okso-2,3-dihidro-1,3-benzotiazol-7-il)etil]amino}etil)-3-[2-(1-naftil)etoksi]propanamid dihidrobromid, te drugi aktivni sastojak koji je muskarinski antagonist koji je aklidinij bromid, glikopirolat, oksitropij bromid, pirenzepin, telenzepin ili tiotropij bromid.
2. Komplet naznačen time, da sadrži:
pripravak prvog aktivnog sastojaka koji je N-[2-(Dietilamino)etil]-N-(2-{[2-(4-hidroksi-2-okso-2,3-dihidro-1,3-benzotiazol-7-il)etil]amino}etil)-3-[2-(1-naftil)etoksi]propanamid dihidrobromid,
pripravak drugog aktivnog sastojaka koji je muskarinski antagonist kao aklidinij bromid, glikopirolat, oksitropij bromid, pirenzepin, telenzepin ili tiotropij bromid, te proizvoljno,
upute za simultano, sekvencijalno ili odvojeno davanje navedenih pripravaka pacijentu kojem oni trebaju.
3. Farmaceutski pripravak, naznačen time, da sadrži, kao mješavinu:
prvi aktivni sastojak koji je N-[2-(Dietilamino)etil]-N-(2-{[2-(4-hidroksi-2-okso-2,3-dihidro-1,3-benzotiazol-7-il)etil]amino}etil)-3-[2-(1-naftil)etoksi]propanamid dihidrobromid;
drugi aktivni sastojak koji je muskarinski antagonist kao aklidinij bromid, glikopirolat, oksitropij bromid, pirenzepin, telenzepin ili tiotropij bromid; te
farmaceutski prihvatljivu pomoćnu tvar, razrjeđivač ili nosač.
4. Farmaceutski proizvod, komplet ili pripravak, prema bilo kojem od prethodnih zahtjeva, naznačen time, da drugi aktivni sastojak je tiotropij bromid.
5. Farmaceutski proizvod, komplet ili pripravak, prema bilo kojem od zahtjeva od 1-4, naznačen time, da se koristi kod liječenja.
6. Uporaba farmaceutskog proizvoda, kompleta ili pripravka, prema bilo kojem od zahtjeva od 1-4, naznačena time, da se upotrebljava za proizvodnju lijeka za liječenje respiratorne bolesti.
7. Farmaceutski proizvod, komplet ili pripravak, prema bilo kojem od zahtjeva od 1-4, naznačena time, da se koristi kod liječenja respiratorne bolesti.
8. Uporaba prema zahtjevu 6 ili 7, naznačena time, da je respiratorna bolest kronična opstruktivna plućna bolest ili astma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0702456.5A GB0702456D0 (en) | 2007-02-08 | 2007-02-08 | New combination |
| PCT/GB2008/000386 WO2008096111A1 (en) | 2007-02-08 | 2008-02-06 | Combinations of beta- 2 -adrenoceptor agonistic benzothiazolone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110695T1 true HRP20110695T1 (hr) | 2011-11-30 |
Family
ID=37898976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110695T HRP20110695T1 (hr) | 2007-02-08 | 2011-09-28 | Kombinacije beta-2-adrenoceptorskog agonističkog benzotiazolona |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20100029732A1 (hr) |
| EP (2) | EP2117542B1 (hr) |
| JP (1) | JP2010518056A (hr) |
| KR (1) | KR20090114391A (hr) |
| CN (1) | CN101652137A (hr) |
| AR (1) | AR065277A1 (hr) |
| AT (1) | ATE520401T1 (hr) |
| AU (1) | AU2008212713A1 (hr) |
| BR (1) | BRPI0806964A2 (hr) |
| CA (1) | CA2675465A1 (hr) |
| CL (1) | CL2008000379A1 (hr) |
| CO (1) | CO6210723A2 (hr) |
| CY (1) | CY1111932T1 (hr) |
| DK (1) | DK2117542T3 (hr) |
| EC (1) | ECSP099567A (hr) |
| ES (1) | ES2368967T3 (hr) |
| GB (1) | GB0702456D0 (hr) |
| HR (1) | HRP20110695T1 (hr) |
| IL (1) | IL199840A0 (hr) |
| MX (1) | MX2009007865A (hr) |
| PE (1) | PE20081759A1 (hr) |
| PL (1) | PL2117542T3 (hr) |
| PT (1) | PT2117542E (hr) |
| RS (1) | RS51956B (hr) |
| RU (1) | RU2009133255A (hr) |
| SI (1) | SI2117542T1 (hr) |
| TW (1) | TW200843750A (hr) |
| UY (1) | UY30906A1 (hr) |
| WO (1) | WO2008096111A1 (hr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200738658A (en) * | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| TW200738659A (en) * | 2005-08-29 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| TW200745067A (en) | 2006-03-14 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| TW200825084A (en) | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
| TW200833670A (en) | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
| GB0702458D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 668 |
| JP4837800B2 (ja) | 2008-05-13 | 2011-12-14 | アストラゼネカ・アクチエボラーグ | ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体 |
| CA2723909A1 (en) * | 2008-05-13 | 2009-11-19 | Richard James Bull | Pharmaceutical product comprising a muscarinic receptor antagonist and a beta2-adrenoceptor agonist |
| KR20110017456A (ko) | 2008-06-18 | 2011-02-21 | 아스트라제네카 아베 | 호흡기 장애의 치료를 위한 베타2-아드레날린성 수용체 효능제로서 작용하는 벤족사지논 유도체 |
| CA2727908A1 (en) * | 2008-06-20 | 2009-12-23 | Astrazeneca Ab | Pharmaceutical composition comprising a 4-hydroxy-2-oxo-2, 3- dihydro-1, 3-benzothiazol-7-yl compound for modulation of beta2-adrenoreceptor activity |
| TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
| US9827212B2 (en) | 2009-03-18 | 2017-11-28 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating asthma and other lung diseases |
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| WO2011011060A1 (en) | 2009-07-22 | 2011-01-27 | Puretech Ventures | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
| GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
| WO2016038116A1 (en) | 2014-09-09 | 2016-03-17 | Vectura Limited | Formulation comprising glycopyrrolate, method and apparatus |
| EA032221B1 (ru) * | 2015-05-04 | 2019-04-30 | Астразенека Аб | Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap) |
| KR102408292B1 (ko) | 2018-09-28 | 2022-06-10 | 카루나 세러퓨틱스 인코포레이티드 | 무스카린성 수용체 활성화에 의해 개선된 장애의 치료를 위한 조성물 및 방법 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE378109B (hr) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| CO5300399A1 (es) | 2000-02-25 | 2003-07-31 | Astrazeneca Ab | Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen |
| AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
| SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| SE0104251D0 (sv) | 2001-12-14 | 2001-12-14 | Astrazeneca Ab | Novel compounds |
| SE0301569D0 (sv) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
| SA04250253B1 (ar) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
| SE0302486D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| GB0324790D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Amide derivatives |
| GB0402797D0 (en) * | 2004-02-09 | 2004-03-10 | Novartis Ag | Organic compounds |
| SE0401762D0 (sv) | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
| US7605168B2 (en) | 2004-09-03 | 2009-10-20 | Plexxikon, Inc. | PDE4B inhibitors |
| AU2005300150A1 (en) | 2004-10-29 | 2006-05-04 | Astrazeneca Ab | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases |
| WO2006098353A1 (ja) | 2005-03-15 | 2006-09-21 | Kyowa Hakko Kogyo Co., Ltd. | 外用剤 |
| TW200738658A (en) * | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| CA2657639A1 (en) | 2006-07-19 | 2008-01-24 | Astrazeneca Ab | Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity |
-
2007
- 2007-02-08 GB GBGB0702456.5A patent/GB0702456D0/en not_active Ceased
-
2008
- 2008-02-04 TW TW097104221A patent/TW200843750A/zh unknown
- 2008-02-06 CN CN200880010926A patent/CN101652137A/zh active Pending
- 2008-02-06 EP EP08702047A patent/EP2117542B1/en active Active
- 2008-02-06 WO PCT/GB2008/000386 patent/WO2008096111A1/en active Application Filing
- 2008-02-06 RS RS20110435A patent/RS51956B/en unknown
- 2008-02-06 PT PT08702047T patent/PT2117542E/pt unknown
- 2008-02-06 MX MX2009007865A patent/MX2009007865A/es not_active Application Discontinuation
- 2008-02-06 JP JP2009548730A patent/JP2010518056A/ja not_active Withdrawn
- 2008-02-06 KR KR1020097016587A patent/KR20090114391A/ko not_active Application Discontinuation
- 2008-02-06 BR BRPI0806964-6A2A patent/BRPI0806964A2/pt not_active IP Right Cessation
- 2008-02-06 US US12/526,328 patent/US20100029732A1/en not_active Abandoned
- 2008-02-06 PL PL08702047T patent/PL2117542T3/pl unknown
- 2008-02-06 RU RU2009133255/15A patent/RU2009133255A/ru not_active Application Discontinuation
- 2008-02-06 CA CA002675465A patent/CA2675465A1/en not_active Abandoned
- 2008-02-06 ES ES08702047T patent/ES2368967T3/es active Active
- 2008-02-06 EP EP11163020A patent/EP2364704A1/en not_active Withdrawn
- 2008-02-06 AU AU2008212713A patent/AU2008212713A1/en not_active Abandoned
- 2008-02-06 AT AT08702047T patent/ATE520401T1/de active
- 2008-02-06 SI SI200830397T patent/SI2117542T1/sl unknown
- 2008-02-06 CL CL200800379A patent/CL2008000379A1/es unknown
- 2008-02-06 DK DK08702047.5T patent/DK2117542T3/da active
- 2008-02-07 PE PE2008000269A patent/PE20081759A1/es not_active Application Discontinuation
- 2008-02-07 US US12/027,424 patent/US20080242649A1/en not_active Abandoned
- 2008-02-08 UY UY30906A patent/UY30906A1/es unknown
- 2008-02-08 AR ARP080100560A patent/AR065277A1/es not_active Application Discontinuation
-
2009
- 2009-07-13 IL IL199840A patent/IL199840A0/en unknown
- 2009-07-21 CO CO09075448A patent/CO6210723A2/es not_active Application Discontinuation
- 2009-08-06 EC EC2009009567A patent/ECSP099567A/es unknown
-
2011
- 2011-09-28 HR HR20110695T patent/HRP20110695T1/hr unknown
- 2011-10-12 CY CY20111100976T patent/CY1111932T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP099567A (es) | 2009-09-29 |
| US20100029732A1 (en) | 2010-02-04 |
| AU2008212713A1 (en) | 2008-08-14 |
| PE20081759A1 (es) | 2009-01-31 |
| WO2008096111A1 (en) | 2008-08-14 |
| MX2009007865A (es) | 2009-07-31 |
| RS51956B (en) | 2012-02-29 |
| BRPI0806964A2 (pt) | 2014-04-08 |
| ATE520401T1 (de) | 2011-09-15 |
| RU2009133255A (ru) | 2011-03-20 |
| CL2008000379A1 (es) | 2008-10-24 |
| US20080242649A1 (en) | 2008-10-02 |
| AR065277A1 (es) | 2009-05-27 |
| EP2117542B1 (en) | 2011-08-17 |
| SI2117542T1 (sl) | 2011-11-30 |
| TW200843750A (en) | 2008-11-16 |
| PT2117542E (pt) | 2011-10-06 |
| JP2010518056A (ja) | 2010-05-27 |
| UY30906A1 (es) | 2008-09-30 |
| GB0702456D0 (en) | 2007-03-21 |
| ES2368967T3 (es) | 2011-11-24 |
| CO6210723A2 (es) | 2010-10-20 |
| KR20090114391A (ko) | 2009-11-03 |
| DK2117542T3 (da) | 2011-10-31 |
| CY1111932T1 (el) | 2015-11-04 |
| EP2364704A1 (en) | 2011-09-14 |
| PL2117542T3 (pl) | 2011-12-30 |
| EP2117542A1 (en) | 2009-11-18 |
| IL199840A0 (en) | 2010-04-15 |
| CA2675465A1 (en) | 2008-08-14 |
| CN101652137A (zh) | 2010-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110695T1 (hr) | Kombinacije beta-2-adrenoceptorskog agonističkog benzotiazolona | |
| UY30903A1 (es) | Nuevas sformas de sales de n-[2-(dietilamino)etil]-n-(2-{[2-(4-hidorxi-2-oxo-2,3-dihidro-1,3-benzotiazol-7-il)etil]amino}etil)-3-[2-(1-naftil)etoxi]propanamida, composiciones comprendiéndolas, procesos de preparacion y aplicaciones. | |
| HRP20161379T1 (hr) | Inhibitori hepatitis c virusa | |
| JP2008539268A5 (hr) | ||
| AR077277A1 (es) | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer | |
| JP2012532874A5 (hr) | ||
| ECSP088405A (es) | Nuevos derivados de pirimidina y su uso en terapia, así como el uso de derivados de pirimidina en la fabricación de un medicamento para la prevención y/o tratamiento de la enfermedad de alzheimer | |
| AR077638A1 (es) | Compuesto de (metanosulfonil -piperidin )-( alcoxi-aril) -tetrahidro- piridina , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de diabetes u obesidad | |
| JP2013542247A5 (hr) | ||
| JP2010132695A5 (hr) | ||
| BR112014000371A2 (pt) | derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença | |
| EA201390332A1 (ru) | Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов | |
| MD4430B1 (ro) | Compoziţii şi metode de tratament al hepatitei virale C | |
| EA201100305A1 (ru) | Лечение респираторных заболеваний | |
| EP2607363A4 (en) | CONDENSED RING COMPOUND FOR USE AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | |
| MY174002A (en) | Combination theraphy for the treatment of diabetes | |
| AR062886A1 (es) | Compuestos de tiazol pirazolopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento | |
| WO2008154083A3 (en) | Compounds, compositions and methods for the treatment of synucleinopathies | |
| AR060974A1 (es) | Compuesto de 4-piridinona, su uso para la preparacion de un medicamento, composicion farmaceutica que lo comprende, proceso para su preparacion y proceso para la preparacion de un compuesto intermediario de utilidad en el anterior | |
| BR112014001798A2 (pt) | compostos de tetraciclina 9-aminometila substituídos | |
| PE20081789A1 (es) | Composicion farmaceutica que contiene aclidino | |
| AR076175A1 (es) | Combinaciones para el tratamiento de enfermedades respiratorias. | |
| AR054508A1 (es) | Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla | |
| MX2010001352A (es) | Derivados de n-(2-tiazolil)-amida para el tratamiento de obesidad, diabetes y enfermedades cardiovasculares. | |
| Paccaly et al. | Absence of clinically relevant drug interaction between delamanid, a new drug for multidrug-resistant tuberculosis (MDR-TB) and tenofovir or lopinavir/ritonavir in healthy subjects |